How to buy Blueprint Medicines stock (BPMC)

Blueprint Medicines is a biotechnology business based in the US. Blueprint Medicines shares (BPMC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $90.14 – a decrease of 3.27% over the previous week. Blueprint Medicines employs 638 staff and has a trailing 12-month revenue of around $434.4 million.

Our top picks for where to buy Blueprint Medicines stock

Buy Blueprint Medicines stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Blueprint Medicines stock price (NASDAQ: BPMC)

Use our graph to track the performance of BPMC stocks over time.

Blueprint Medicines shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$90.14
52-week range	$72.24 - $121.90
50-day moving average more info button	$92.18
200-day moving average more info button	$96.69
Wall St. target price	$125.58
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.09

Is it a good time to buy Blueprint Medicines stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Blueprint Medicines price performance over time

Historical closes compared with the close of $91.78 from 2024-12-18

1 week (2024-12-13)	-1.51%
1 month (2024-11-21)	-5.01%
3 months (2024-09-20)	0.11%
6 months (2024-06-20)	-12.76%

1 year (2023-12-20)	9.11%
2 years (2022-12-20)	109.59%
3 years (2021-12-20)	105.79
5 years (2019-12-20)	15.48%

Blueprint Medicines financials

Revenue TTM	$434.4 million
Gross profit TTM	$177.3 million
Return on assets TTM	-14.97%
Return on equity TTM	-49.66%
Profit margin	-29.48%
Book value	$4.94
Market Capitalization more info button	$5.8 billion

TTM: trailing 12 months

Blueprint Medicines share dividends

We're not expecting Blueprint Medicines to pay a dividend over the next 12 months.

Blueprint Medicines share price volatility

Over the last 12 months, Blueprint Medicines's shares have ranged in value from as little as $72.24 up to $121.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Blueprint Medicines's is 0.59. This would suggest that Blueprint Medicines's shares are less volatile than average (for this exchange).

Blueprint Medicines overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc. ; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc. ; Hoffmann-La Roche Inc.

Frequently asked questions

null
What percentage of Blueprint Medicines is owned by insiders or institutions?
Currently 0.896% of Blueprint Medicines shares are held by insiders and 104.738% by institutions. How many people work for Blueprint Medicines?
Latest data suggests 638 work at Blueprint Medicines. When does the fiscal year end for Blueprint Medicines?
Blueprint Medicines's fiscal year ends in December. Where is Blueprint Medicines based?
Blueprint Medicines's address is: 45 Sidney Street, Cambridge, MA, United States, 02139 What is Blueprint Medicines's ISIN number?
Blueprint Medicines's international securities identification number is: US09627Y1091 What is Blueprint Medicines's CUSIP number?
Blueprint Medicines's Committee on Uniform Securities Identification Procedures number is: 09627Y109